{"id":"NCT03537508","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US","officialTitle":"A Phase III, Partially Modified Double-blind, Randomized, Parallel-group, Active-controlled, Multi-center Study to Compare the Immunogenicity and Describe the Safety of MenACYW Conjugate Vaccine and MENVEO® When Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in the United States","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-04-25","primaryCompletion":"2023-09-22","completion":"2023-09-22","firstPosted":"2018-05-25","resultsPosted":"2024-10-15","lastUpdate":"2024-10-15"},"enrollment":2627,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Healthy Volunteers (Meningococcal Infection)"],"interventions":[{"type":"BIOLOGICAL","name":"MenACYW conjugate vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"MenACYW-135 conjugate vaccine","otherNames":["MENVEO®"]},{"type":"BIOLOGICAL","name":"DTaP-IPV//Hib vaccine","otherNames":["Pentacel®"]},{"type":"BIOLOGICAL","name":"Pneumococcal 13-valent conjugate vaccine","otherNames":["PREVNAR 13®"]},{"type":"BIOLOGICAL","name":"Pentavalent rotavirus vaccine","otherNames":["RotaTeq®"]},{"type":"BIOLOGICAL","name":"Hepatitis B vaccine","otherNames":["ENGERIX-B®"]},{"type":"BIOLOGICAL","name":"Measles, mumps, rubella (MMR) vaccine","otherNames":["M-M-R® II"]},{"type":"BIOLOGICAL","name":"Varicella vaccine","otherNames":["VARIVAX®"]},{"type":"BIOLOGICAL","name":"Hepatitis A vaccine","otherNames":["HAVRIX®"]}],"arms":[{"label":"Group 1a","type":"EXPERIMENTAL"},{"label":"Group 1b","type":"EXPERIMENTAL"},{"label":"Group 2a","type":"ACTIVE_COMPARATOR"},{"label":"Group 2b","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study was to compare the immunogenicity and describe the safety of MenACYW conjugate vaccine and MENVEO® when both are administered concomitantly with routine pediatric vaccines to healthy infants and toddlers in the US.","primaryOutcome":{"measure":"Groups 1a and 2a: Percentage of Participants With Vaccine Seroresponse Measured by Serum Bactericidal Assay Using Human Complement (hSBA) at Day 30 Post 12-Month Vaccination","timeFrame":"Day 30 post 12-month vaccination (Month 13)","effectByArm":[{"arm":"Group 1a:MenACYW Conjugate Vaccine (Post 12-month Vaccination)","deltaMin":79.4,"sd":null},{"arm":"Group 2a: MENVEO (Post 12-month Vaccination)","deltaMin":77.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"42 Days","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":25},"locations":{"siteCount":70,"countries":["United States","Puerto Rico"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":99,"n":1727},"commonTop":["Injection Site Pain","Irritability","Crying","Somnolence","Injection Site Erythema"]}}